Literature DB >> 12413498

Impact of atrial fibrillation on mortality in patients with chronic heart failure.

Maarten P van den Berg1, Isabelle C van Gelder, Dirk J van Veldhuisen.   

Abstract

Chronic heart failure and atrial fibrillation often occur together. The aim of the study is to review the available literature on the impact of atrial fibrillation on mortality in patients with heart failure. Using MEDLINE six full papers were identified. In the studies with severe heart failure atrial fibrillation did not emerge as an independent predictor of mortality beyond standard clinical variables. In contrast, atrial fibrillation was associated with increased mortality in case of mild-to-moderate heart failure. Copyright 2002 European Society of Cardiology

Entities:  

Mesh：

Year:  2002        PMID： 12413498     DOI： 10.1016/s1388-9842(02)00094-6

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


  11 in total

Review 1.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

Review 2.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

Review 3.  Atrial fibrillation: basic mechanisms, remodeling and triggers.

Authors:  Akiko Shiroshita-Takeshita; Bianca J J M Brundel; Stanley Nattel
Journal:  J Interv Card Electrophysiol       Date:  2005-09       Impact factor: 1.900

Review 4.  [Rate versus rhythm control with and without heart failure].

Authors:  Florian Straube; Uwe Dorwarth; Sabine Janko; Ellen Hoffmann
Journal:  Herz       Date:  2008-12       Impact factor: 1.443

5.  Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study.

Authors:  Mariana S Parahuleva; Sandip Kanse; Hans Hölschermann; Kirila Zheleva; Daniel Zandt; Michael Worsch; Behnoush Parviz; Norbert Güttler; Harald Tillmanns; Andreas Böning; Ali Erdogan
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

6.  Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation.

Authors:  Andreas S Kalogeropoulos; Sotirios Tsiodras; Angelos G Rigopoulos; Eleftherios A Sakadakis; Andreas Triantafyllis; Dimitrios Th Kremastinos; Ioannis Rizos
Journal:  BMC Cardiovasc Disord       Date:  2011-12-28       Impact factor: 2.298

7.  Newly developed atrial fibrillation progresses to a more severe INTERMACS score in a patient with advanced heart failure due to dilated cardiomyopathy.

Authors:  Akihito Saito; Eisuke Amiya; Masaru Hatano; Yumiko Hosoya; Hisataka Maki; Daisuke Nitta; Shun Minatsuki; Masafumi Watanabe; Issei Komuro
Journal:  Clin Case Rep       Date:  2017-11-01

8.  Meta-analysis of effect of vernakalant on conversion of atrial fibrillation.

Authors:  He Yan; Thi Thi Aung; Zhong Guoqiang; Zhang Zhengnan; Ji Lan; Zeng Zhiyu
Journal:  BMC Res Notes       Date:  2013-03-13

9.  All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study.

Authors:  Tommy Andersson; Anders Magnuson; Ing-Liss Bryngelsson; Ole Frøbert; Karin M Henriksson; Nils Edvardsson; Dritan Poçi
Journal:  Eur Heart J       Date:  2013-01-14       Impact factor: 29.983

10.  Metagenomic data-mining reveals enrichment of trimethylamine-N-oxide synthesis in gut microbiome in atrial fibrillation patients.

Authors:  Kun Zuo; Xiaoqing Liu; Pan Wang; Jie Jiao; Chunming Han; Zheng Liu; Xiandong Yin; Jing Li; Xinchun Yang
Journal:  BMC Genomics       Date:  2020-07-30       Impact factor: 3.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.